Absci (ABSI) FY Conference Transcript

Summary of Abzai (ABSI) FY Conference Call Company Overview - Abzai is a generative AI drug creation company focused on solving complex biological problems to deliver differentiated assets to patients faster [1] - The company has a data-first approach and has developed a world-class AI platform leveraging expertise from leading tech companies [2] Core Technology and Pipeline - Abzai's original technology involves scaling protein-protein interactions, allowing the screening of millions of antibodies [2] - The company employs a "lab in the loop" model, enabling rapid iteration on model designs and architectures [6] - Abzai is targeting hard-to-drug targets such as ion channels and GPCRs, with a strong internal pipeline and partnerships with large pharma [3][13] Key Assets - ABS 101: An anti-TL1A antibody for inflammatory bowel disease (IBD) that entered the clinic in May 2025. It shows a 3x increase in target engagement compared to first-generation antibodies and is designed for convenient at-home self-injection [4][17][18] - ABS 201: An anti-prolactin receptor antibody targeting androgenic alopecia, which affects over 80 million patients in the US. It aims to shift hair follicles back into the active growth phase, showing promising durability and efficacy compared to standard treatments like minoxidil [21][22][32] Clinical Data and Efficacy - ABS 101 is expected to have a phase one interim readout in the second half of 2025, with potential for quarterly dosing due to its extended half-life [18][34] - ABS 201 has demonstrated superior efficacy in preclinical models, with faster hair regrowth compared to minoxidil and high bioavailability [28][29][30] Market Potential - The market for androgenic alopecia treatments is significant, with over 80 million Americans affected. The company sees ABS 201 as a first-in-class asset with untapped market potential [31][32] - The company anticipates a large pharma partnership by the end of 2025, which could provide significant upfront capital [34] Strategic Partnerships - Abzai has established partnerships with large pharma and biotech firms to leverage their domain expertise and enhance its AI capabilities [13][14] - Collaborations with organizations like Caltech and the Gates Foundation have led to breakthroughs in drug design, particularly for hard-to-drug targets like HIV [9][10] Conclusion - Abzai is positioned to leverage generative design to create differentiated biologics, with a strong pipeline and strategic partnerships aimed at accelerating drug development and improving patient outcomes [35]